Literature DB >> 17890873

Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. The chronic renal impairment in Birmingham (CRIB) study.

Daniel Zehnder1, Martin J Landray, David C Wheeler, William Fraser, Lisa Blackwell, Sarah Nuttall, Sue V Hughes, John Townend, Charles Ferro, Colin Baigent, Martin Hewison.   

Abstract

BACKGROUND: Disturbances in mineral and vitamin D metabolism, which affect parathyroid hormone (PTH) synthesis, are well recognized in patients receiving dialysis. However, it is unclear at what stage of chronic kidney disease (CKD) these abnormalities develop.
METHODS: The associations between CKD stages 3 and 5, and alterations of calcium, phosphate, vitamin D and PTH concentrations were assessed in 249 patients (mean age 61 years, 66% male) and 79 age- and sex-matched healthy controls.
RESULTS: As compared to controls, serum phosphate concentrations were elevated among CKD patients (1.40 vs. 1.11 mmol/l; p < 0.0001). And levels of both 25-hydroxyvitamin D (42.1 vs. 60.4 nmol/l; p < 0.0001) and 1,25-dihydroxyvitamin D (58.2 vs. 119.5 pmol/l; p < 0.0001) were lower among patients with CKD, even among those with only stage 3 CKD and despite 73% of patients receiving vitamin D supplements. The ratio of 1,25-dihydroxy- to 25-hydroxyvitamin D was lower than controls, even among patients with stage 3 CKD (p = 0.0001), and this ratio diminished with advancing renal impairment. Concomitant elevations were observed in intact PTH (13.8 vs. 4.2 pmol/l; p < 0.0001) and whole PTH (7.9 vs. 2.7 pmol/l; p < 0.0001).
CONCLUSION: Impaired conversion of 25-hydroxy- to 1,25-dihydroxyvitamin D is an early feature of renal disease, and progresses as renal function deteriorates. (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17890873     DOI: 10.1159/000108652

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  17 in total

1.  Vitamin D status of children receiving chronic dialysis.

Authors:  Basema I Dibas; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2012-06-03       Impact factor: 3.714

2.  Ethnic differences in 25-hydroxyvitamin D levels and response to treatment in CKD.

Authors:  Iris Sanchez; Roberto Mangoo-Karim; Jason R Stubbs; George P Yanev; James B Wetmore
Journal:  Int Urol Nephrol       Date:  2012-05-30       Impact factor: 2.370

3.  Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.

Authors:  Pieter Evenepoel; Björn Meijers; Liesbeth Viaene; Bert Bammens; Kathleen Claes; Dirk Kuypers; Dirk Vanderschueren; Yves Vanrenterghem
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-06       Impact factor: 8.237

4.  Serum free light chains and the risk of ESRD and death in CKD.

Authors:  Richard Haynes; Colin A Hutchison; Jonathan Emberson; Tanaji Dasgupta; David C Wheeler; John N Townend; Martin J Landray; Paul Cockwell
Journal:  Clin J Am Soc Nephrol       Date:  2011-10-27       Impact factor: 8.237

5.  Prevalence of 25-hydroxyvitamin D deficiency in Korean patients with anemia.

Authors:  Eun-Hyung Yoo; Hyun-Jung Cho
Journal:  J Clin Lab Anal       Date:  2014-05-05       Impact factor: 2.352

6.  Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis.

Authors:  Haimanot Wasse; Rong Huang; Qi Long; Salman Singapuri; Paolo Raggi; Vin Tangpricha
Journal:  Am J Clin Nutr       Date:  2012-01-11       Impact factor: 7.045

Review 7.  Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?

Authors:  James B Wetmore; L Darryl Quarles
Journal:  Nat Clin Pract Nephrol       Date:  2008-10-28

8.  Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study.

Authors:  Martin J Landray; Jonathan R Emberson; Lisa Blackwell; Tanaji Dasgupta; Rosita Zakeri; Matthew D Morgan; Charlie J Ferro; Susan Vickery; Puja Ayrton; Devaki Nair; R Neil Dalton; Edmund J Lamb; Colin Baigent; Jonathan N Townend; David C Wheeler
Journal:  Am J Kidney Dis       Date:  2010-10-30       Impact factor: 8.860

9.  Medication-prescribing patterns of primary care physicians in chronic kidney disease.

Authors:  Yoshiyuki Morishita; Akihiko Numata; Atushi Miki; Mari Okada; Kenichi Ishibashi; Fumi Takemoto; Yasuhiro Ando; Shigeaki Muto; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2013-11-02       Impact factor: 2.801

Review 10.  The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease.

Authors:  Ladan Zand; Rajiv Kumar
Journal:  Endocrinol Metab Clin North Am       Date:  2017-09-29       Impact factor: 4.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.